A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Clinical research in 2024 is progressing rapidly, driven by pioneering studies, technological innovation, and evolving regulatory frameworks that …
Clinical research worldwide is rapidly transforming through new digital strategies—especially in the field of rare diseases. Recent months …
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
Already a subscriber? Log in